Public Health Agency of Canada | Agence de la santé publique du Canada

**Protected B** When Completed

# Report Of Adverse Events Following Immunization (AEFI)

**Instructions: For more complete instructions and definitions, refer to the *user guide* at:**
https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization/user-guide-completion-submission-aefi-reports.html

Report events which have a temporal association with a vaccine and which cannot be clearly attributed to other causes. A causal relationship does not need to be proven, and submitting a report does not imply causality.

Of particular interest are those AEFIs which:

a. Meet one or more of the seriousness criteria
b. Are unexpected regardless of seriousness.

Refer to the user guide, Background Information for additional clarification.

**Note:**

- **The numbers below correspond to the numbered sections of the form.**
- **All dates should be captured in the following format: YYYY/MM/DD.**
- **When reporting an AEFI, check one of the boxes on the top right hand corner of the first page of the AEFI form to indicate whether it is an "initial" or "follow up" report. For all follow up reports, please specify the "Unique Episode number".**

**1a.** The **"Unique episode number"** is assigned by the Province/Territory. Leave it blank unless authorized to assign it.

**1b.** The **"Region number"** is a number that corresponds to a given health unit. Leave it blank if it doesn't apply to your locale.

**2.** The "IMPACT LIN" is assigned by Impact nurse monitors (LIN: Local Inventory Number).

**3.** The information captured in this section is confidential and is intended for use **only** by the regional and/or provincial/territorial health officials.

**4a.** Indicate the Province/Territory where the vaccine was administered, abbreviations may be used.

**4c.** Provide all information as requested in the table. For the "Dose #", provide the number in series (1, 2, 3, 4, 5 or booster) if known.
For the Influenza vaccine, unless a patient receives two doses in one season, the "Dose #" should be recorded as "1".

**7a.** Indicate the highest impact of the AEFI on the patient's daily activities as assessed by the patient or the parent/caregiver.

**7c.** Provide details of any investigations or treatments in section 10. If the patient was already in hospital when immunized and the immunization resulted in a longer hospital stay, indicate "Resulted in prolongation of existing hospitalization" and provide the number of days by which the patient's hospital stay was prolonged. For all hospitalizations, indicate the date of admission and discharge.

**8.** MOH/MHO: Medical Officer of Health, MD: Medical Doctor, RN: Registered Nurse.

**9.** Choose, from section 9 (AEFI details), the description that best fits the AEFI being reported. Make sure to record the time of onset and duration of signs/symptoms using the most appropriate time unit: Days, Hours or Minutes. Provide additional details of any investigation, therapy, and other information as appropriate in section 10.

**11.** This section is to be completed by the MOH/MHO, MD, RN or their designate who are assigned to provide public health recommendations according to the P/T best practices.

**12.** Information in this section is not collected by all P/Ts.

**Return completed form to your local public health unit address at:**

| | | |
|---|---|---|
| Alberta (AB) | Northwest Territories (NT) | Quebec (QC) |
| British Columbia (BC) | Nova Scotia (NS) | Saskatchewan (SK) |
| Manitoba (MB) | Nunavut (NU) | Yukon (YT) |
| New Brunswick (NB) | Ontario (ON) | Canadian Forces Health Services (CFHS) |
| Newfoundland and Labrador (NL) | Prince Edward Island (PE) | Public Health Agency of Canada (PHAC) |

PHAC 03/2019

Canada

◯ Initial report
◯ Follow up report (Unique episode #)

**1a. Unique episode #:** **1b. Region #:** **2. IMPACT LIN:**

**3. Patient Identification**

**First name:** **Last name:** **Health number:**

**Address of usual residence:**

**Province/Territory:** **Postal code:** **Phone:** **ext #:**

**Information Source: First name:** **Last name:** **Relation to patient:**

**Contact info, if different:**

**4. Information at Time of Immunization and AEFI Onset**

**4a. At time of immunization: Province/Territory of immunization:**

**Date vaccine administered** (YYYY/MM/DD)**:** (hr: ◯ am/ ◯ pm) **Date of birth** (YYYY/MM/DD)**:** **Age:**

**Sex:** ◯ Male ◯ Female ◯ Other ☐ **Pregnant at time of immunization:** ☐ Gestation ☐ weeks ☐ days

**4b. Medical history (up to the time of AEFI onset)** *(Check all that apply and provide details in section 10)*

☐ Concomitant medication(s) ☐ Known medical conditions/allergies ☐ Acute illness/injury

| 4c. Immunizing agent | Trade name | Manufacturer | Lot number | Dose # | Dosage/unit | Route | Site |
|---|---|---|---|---|---|---|---|
| | | | | | / | | |
| | | | | | / | | |
| | | | | | / | | |
| | | | | | / | | |
| | | | | | / | | |
| | | | | | / | | |
| | | | | | / | | |

**5. Immunization Errors**

**Did this AEFI follow an incorrect immunization?** ◯ No ◯ Unknown ◯ Yes

*(If Yes, choose all that apply and provide details in section 10)*

☐ Given outside the recommended age limits ☐ Product expired
☐ Wrong vaccine given ☐ Incorrect route
☐ Dose exceeded that recommended for age ☐ Other, specify:

**6. Previous AEFI**

**Did an AEFI follow a previous dose of any of the above immunizing agents (Table 4c)?**

*(Choose one of the following)*

◯ No ◯ Yes *(Provide details in section 10)*
◯ Unknown ◯ Not applicable *(no prior doses)*

*Note: Discuss with patient or his/her parent/caregiver reason for reporting and confidentiality of information*

**Unique episode #:** ____ **Region #:** ____ **IMPACT LIN:** ____

## 7. Impact of AEFI, Outcome, and Level of Care Obtained

**7a. Highest impact of AEFI:** (*Choose one of the following)*

- ◯ Did not interfere with daily activities
- ◯ Interfered with but did not prevent daily activities
- ◯ Prevented daily activities

**7b. Outcome at time of report:** *(Provide details in section 10 for items with †)*

- ◯ Death† Date **(YYYY/MM/DD):** ____
- ◯ Permanent disability/incapacity † ◯ Not yet recovered †
- ◯ Fully recovered ◯ Unknown

**7c. Highest level of care obtained:** (*Choose one of the following)*

◯ Unknown ◯ None ◯ Telephone advice from a health professional ◯ Non-urgent visit ◯ Emergency visit

◯ Required hospitalization (____ days) **OR** ◯ Resulted in prolongation of existing hospitalization (by ____ days)

Date of hospital admission (YYYY/MM/DD)**:** ____ Date of hospital discharge **(**YYYY/MM/DD**):** ____

**7d. Treatment received:** ◯ No ◯ Unknown ◯ Yes *(Provide details of all treatments including self-treatment, in section 10)*

## 8. Reporter Information

**Setting :** ◯ Physician office ◯ Public health ◯ Hospital ◯ Workplace Clinic ◯ Other, specify: ____

Name: ____ Phone: ____ Ext #: ____ Fax: ____

Address: ____

City: ____ Prov/Terr: ____ Postal code: ____ Date reported (YYYY/MM/DD): ____

Signature:_____ ◯ MD ◯ RN ◯ Impact ◯ Pharmacist ◯ Other, specify: ____

**9. AEFI Details:** Complete all sections as appropriate; for each, check all signs/symptoms that apply. Item(s) with asterisk (*) should be diagnosed by a physician. If not, provide sufficient information to support the selected item(s). Use Section 10 foradditional information including, clinical details and test results.

☐ **9a. Local reaction at or near vaccination site**

**Interval:** ____ Min ____ Hrs ____ Days from immunization to onset of 1st symptom or sign

**Duration:** ____ Min ____ Hrs ____ Days from onset of 1st symptom/sign to resolution of all symptoms/signs

☐ Infected abscess ☐ Sterile abscess ☐ Cellulitis ☐ Nodule ☐ Reaction crosses joint ☐ Lymphadenitis

☐ Other, specify: ____

*For any vaccination site reaction indicated above, check all that apply below and provide details in section 10:*

☐ Swelling ☐ Pain ☐ Tenderness ☐ Erythema ☐ Warmth ☐ Induration ☐ Rash

☐ Largest diameter of vaccination site reaction: ____ cm Site(s) of reaction ____ (e.g. LA, RA)

☐ Palpable fluctuance ☐ Fluid collection shown by imaging technique (e.g. MRI, CT, ultrasound)

☐ Spontaneous/surgical drainage ☐ Microbial results ☐ Lymphangitic streaking ☐ Regional lymphadenopathy

**Unique episode #:** _____ **Region #:** _____ **IMPACT LIN:** _____

☐ **9b. Allergic and Allergic-like events**

**Interval:** ☐ Min ☐ Hrs ☐ Days from immunization to onset of 1st symptom or sign

**Duration:** ☐ Min ☐ Hrs ☐ Days from onset of 1st symptom/sign to resolution of all symptoms/signs

*Choose one of the following:* ○ **Anaphylaxis** ○ **Oculo-Respiratory Syndrome (ORS)** ○ **Other allergic events**

**Skin /mucosal**

☐ Urticaria ☐ Erythema ☐ Pruritus ☐ Prickle sensation ☐ Flushing ☐ Other Rash

○ **Generalized** ○ **Localized *(site)*** _____

☐ **Angioedema:** ☐ Tongue ☐ Throat ☐ Uvula ☐ Larynx ☐ Lip

☐ Eyelids ☐ Face ☐ Limbs ☐ Other, *specify:* _____

Eye(s): ☐ Red bilateral ☐ Red unilateral ☐ Itchy

**Cardio-vascular**

☐ Measured hypotension ☐ ↓ central pulse volume ☐ Capillary refill time > 3 sec

☐ Tachycardia ☐ ↓ or loss of consciousness (*Duration*) _____

**Respiratory**

☐ Sneezing ☐ Rhinorrhea ☐ Hoarse voice ☐ Sensation of throat closure ☐ Stridor

☐ Dry cough ☐ Tachypnea ☐ Wheezing ☐ Indrawing/retractions ☐ Grunting

☐ Cyanosis ☐ Sore throat ☐ Difficulty swallowing ☐ Difficulty breathing ☐ Chest tightness

**Gastrointestinal**

☐ Diarrhea ☐ Abdominal pain ☐ Nausea ☐ Vomiting

☐ **9c. Neurologic events**

**Interval:** ☐ Min ☐ Hrs ☐ Days from immunization to onset of 1st symptom or sign

**Duration:** ☐ Min ☐ Hrs ☐ Days from onset of 1st symptom/sign to resolution of all symptoms/signs

☐ **Meningitis*** ☐ **Encephalopathy/Encephalitis*** ☐ **Guillain-Barre Syndrome (GBS)*** ☐ **Bell's Palsy***

☐ **Other Paralysis*** ☐ **Seizure** ☐ **Anaesthesia** ☐ **Paraesthesia** ☐ **Other neurologic diagnosis*, *specify:*** _____

☐ Depressed/altered level of consciousness ☐ Lethargy ☐ Personality change lasting ≥ 24hrs ☐ Focal or multifocal neurologic sign(s)

☐ Fever (≥ 38.0°C) ☐ CSF abnormality ☐ EEG abnormality ☐ EMG abnormality ☐ Neuroimaging abnormality

☐ Brain/spinal cord histopathologic abnormality ☐ Numbness ☐ Tingling ☐ Burning ☐ Formication ☐ Other, *specify:* _____

**Type of Seizure:**

○ **Partial Seizure** OR ○ **Generalized Seizure** (*Specify*: ○ Tonic ○ Clonic ○ Tonic-Clonic ○ Atonic ○ Absence ○ Myoclonic)

**Seizure details:** ☐ Sudden loss of consciousness ○ Yes ○ No ○ Unknown

☐ Witnessed by healthcare professional ○ Yes ○ No ○ Unknown

☐ Previous history of seizures (*Specify*: ○ Febrile ○ Afebrile ○ Unknown type)

☐ **9d. Other events**

**Interval:** ☐ Min ☐ Hrs ☐ Days from immunization to onset of 1st symptom or sign

**Duration:** ☐ Min ☐ Hrs ☐ Days from onset of 1st symptom/sign to resolution of all symptoms/signs

☐ **Hypotonic-Hyporesponsive Episode (age < 2 years)** ☐ Limpness ☐ Pallor/cyanosis ☐ ↓ responsiveness/unresponsiveness

☐ **Persistent crying** (*Continuous and unaltered crying for ≥ 3 hours)*

☐ **Intussusception***

☐ **Arthritis** ☐ Joint redness ☐ Joint warm to touch ☐ Joint pain ☐ Joint swelling ☐ Inflammatory changes in synovial fluid

☐ **Parotitis** *(Parotid gland swelling with pain and/or tenderness)*

☐ **Rash *(Non-allergic)*** ○ Generalized ○ Localized (*Site*)

**Unique episode #:** ☐ **Region #:** ☐ **IMPACT LIN:** ☐

☐ **Thrombocytopenia*** ☐ Clinical evidence of bleeding ☐ Platelet count < $150 \times 10^9$/L ☐ Petechial rash ☐ Other clinical evidence of bleeding

☐ **Severe vomiting** *(Severe enough to interfere with daily routine)*

☐ **Severe diarrhea** *(Severe enough to interfere with daily routine)*

☐ **Fever ≥ 38.0°C** *(NOTE: report **only** if fever occurs in conjunction with another reportable event. For fever in a neurological event, use section 9c)*

☐ **Other serious or unexpected event(s) not listed in the form** (*Describe in section 10)*

**10. Supplementary information:** *(Please indicate the section number when providing details. Please provide details of any investigation or treatment for the recorded AEFI. If not, provide sufficient information to support the selected item(s)).*

**11. Recommendations for future immunization(s) according to the Federal/Provincial/Territorial best practices.**

(*Provide comments, use section 10 if extra space needed*)

| | | |
|---|---|---|
| ☐ No change to immunization schedule | ☐ Controlled setting for next immunization | Other, *specify:* ☐ |
| ☐ Expert referral, *specify:* ☐ | ☐ No further immunizations with: ☐ *specify:* ☐ | |
| ☐ Determine protective antibody level | ☐ Active follow up for AEFI recurrence after next vaccine | |

Name: ☐ Professional status: ◯ MOH/MHO ◯ MD ◯ RN ◯ Other, *specify:* ☐

**Comments:**

Phone: ☐ (ext #: ☐ ) Date (YYYY/MM/DD): ☐ Signature

**12. Follow up information for a subsequent dose of same vaccine(s)** *(Provide details in section 10)*

☐ Vaccine administered without AEFI ☐ Vaccine administered with recurrence of AEFI ☐ Vaccine administered, other AEFI observed
☐ Vaccine administered without information on AEFI ☐ Vaccine not administered